Qiming Venture Partners Portfolio Companies Make 2025 Beijing Top 100 Private Enterprise Rankings

Recently, the 2025 Beijing Top 100 Private Enterprises series rankings were officially released. The series includes the Beijing Top 100 Private Enterprises, Top 100 for Scientific and Technological Innovation, Top 100 for Cultural Industries, Top 100 for Specialized and Sophisticated Enterprises, and Outstanding Social Responsibility Cases. It aims to showcase the development trends and industrial layout of Beijing's private economy, identify a cohort of high-quality private enterprises that align with the "high-end, precision, and advanced" economic structure and can serve as models, and encourage private enterprises to embrace new development philosophies and drive high-quality growth.

Qiming Venture Partners portfolio companies Xiaomi (01810.HK), Meituan (03690.HK), Roborock (688169.SH), Yuanxin Technology, HyperStrong (688411.SH), Zhipu AI, SinoCellTech (688520.SH), Unisound (09678.HK), Sinotau Pharmaceutical, Gan & Lee Pharmaceuticals (603087.SH), QSG (NASDAQ:QSG), 52TOYS, Sino Biological (301047.SZ), and Yuanxin Health Insurance were selected.

Xiaomi, Meituan, Roborock

Yuanxin Technology, HyperStrong

Selected for

Beijing Top 100 Private Enterprises

Meituan, Xiaomi, Zhipu AI

SinoCellTech, Roborock, HyperStrong

Unisound, Sinotau Pharmaceutical, Gan & Lee Pharmaceuticals

Selected for

Beijing Top 100 Private Enterprises for Scientific and Technological Innovation

Roborock, QSG, 52TOYS

Selected for

Beijing Top 100 Private Enterprises for Cultural Industries

Sino Biological, HyperStrong, Yuanxin Health Insurance

Selected for

Beijing Top 100 Specialized and Sophisticated Private Enterprises

Xiaomi, Meituan, Gan & Lee Pharmaceuticals

Selected for

Beijing Private Enterprises Outstanding Social Responsibility Cases

Selection Criteria

• Beijing Top 100 Private Enterprises

This ranking uses total annual revenue for 2024 as the core metric, with comprehensive consideration given to lawful and compliant operations and business integrity. Companies are ranked by total revenue.

• Beijing Top 100 Private Enterprises for Scientific and Technological Innovation

This ranking uses 2024 annual revenue, R&D expenditure, R&D intensity, and R&D personnel as core metrics, with comprehensive consideration given to lawful and compliant operations and business integrity. Rankings are determined through quantitative scoring of core and auxiliary indicators.

• Beijing Top 100 Private Enterprises for Cultural Industries

This ranking follows the nine-category classification standard for cultural industries, inviting enterprises with cultural attributes to participate. It uses 2024 contributions to public cultural services and other social benefits, as well as cultural business revenue, net assets, and net profit as core economic indicators. Receipt of Beijing municipal-level awards serves as a bonus factor, with comprehensive consideration given to lawful and compliant operations and business integrity. Rankings are determined through quantitative scoring of core and auxiliary indicators.

• Beijing Top 100 Specialized and Sophisticated Private Enterprises

This ranking invites companies recognized as Beijing "specialized and sophisticated" SMEs to participate. It uses 2024 operating performance, industrial positioning, years in industry, and R&D and innovation capabilities as core metrics, with comprehensive consideration given to lawful and compliant operations and business integrity. Rankings are determined through quantitative scoring of core and auxiliary indicators.

• Beijing Private Enterprises Outstanding Social Responsibility Cases

This marks the first year the organizers have conducted this selection, examining participation in rural revitalization, promotion of stable employment, engagement in philanthropy, support for green development, and strengthening of industrial workforce development. The evaluation highlights distinctive contributions such as promoting employment for people with disabilities, supporting rural industrial revitalization, and participating in paired assistance and regional collaboration programs. It showcases outstanding examples of Beijing private enterprises fulfilling social responsibility, encouraging more private enterprises to actively participate in public welfare and social responsibility initiatives.

Source | Beijing Federation of Industry and Commerce

Past Coverage

Qiming Stars | 8 Qiming Venture Partners Portfolio Companies Selected for 2024 Beijing Top 100 Private Enterprises Rankings Qiming Stars | WeRide, Cornerstone Robotics Selected for Wealth China Best Design List 2025 Qiming Honors | Qiming Venture Partners Wins 3 Awards Including China Venture Capital Research Institute 2025 China Venture Capital Industry Annual Golden Investment Award

Qiming Venture Partners was founded in 2006. The firm currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, Qiming has focused on investing in outstanding early- and growth-stage companies in Technology and Healthcare.

To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A. Over 80 portfolio companies have become recognized unicorns or super-unicorns.

Many Qiming portfolio companies have grown into the most influential companies in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), SinoCellTech (688520.SH), Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, and others.